J.W. Cole Advisors Inc. Buys 8,839 Shares of Medtronic PLC (NYSE:MDT)

J.W. Cole Advisors Inc. boosted its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 90.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,617 shares of the medical technology company's stock after buying an additional 8,839 shares during the period. J.W. Cole Advisors Inc.'s holdings in Medtronic were worth $1,673,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MDT. Signet Investment Advisory Group Inc. lifted its stake in Medtronic by 10.9% during the first quarter. Signet Investment Advisory Group Inc. now owns 24,362 shares of the medical technology company's stock worth $2,189,000 after purchasing an additional 2,385 shares during the last quarter. Montag A & Associates Inc. lifted its stake in Medtronic by 6.4% during the first quarter. Montag A & Associates Inc. now owns 8,005 shares of the medical technology company's stock worth $725,000 after purchasing an additional 480 shares during the last quarter. IFP Advisors Inc lifted its stake in Medtronic by 20.7% during the first quarter. IFP Advisors Inc now owns 42,596 shares of the medical technology company's stock worth $3,828,000 after purchasing an additional 7,310 shares during the last quarter. OneAscent Financial Services LLC lifted its stake in Medtronic by 4.9% during the first quarter. OneAscent Financial Services LLC now owns 3,772 shares of the medical technology company's stock worth $337,000 after purchasing an additional 175 shares during the last quarter. Finally, Berkeley Capital Partners LLC lifted its stake in Medtronic by 62.8% during the first quarter. Berkeley Capital Partners LLC now owns 31,257 shares of the medical technology company's stock worth $2,809,000 after purchasing an additional 12,061 shares during the last quarter. Institutional investors own 82.06% of the company's stock.

Medtronic Stock Up 0.6%

Medtronic stock traded up $0.53 during trading hours on Friday, hitting $92.85. 2,889,009 shares of the stock traded hands, compared to its average volume of 7,741,114. The firm's 50-day moving average price is $86.91 and its two-hundred day moving average price is $87.44. The company has a current ratio of 1.85, a quick ratio of 1.42 and a debt-to-equity ratio of 0.53. The company has a market cap of $119.08 billion, a PE ratio of 25.65, a PEG ratio of 2.39 and a beta of 0.80. Medtronic PLC has a one year low of $78.32 and a one year high of $96.25.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.04. Medtronic had a return on equity of 14.54% and a net margin of 13.90%. The business had revenue of $8.93 billion for the quarter, compared to analysts' expectations of $8.81 billion. During the same period in the previous year, the firm posted $1.46 EPS. The business's revenue was up 3.9% on a year-over-year basis. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 11th. Stockholders of record on Friday, June 27th were given a $0.71 dividend. This is a boost from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend was Friday, June 27th. Medtronic's payout ratio is currently 78.45%.

Analysts Set New Price Targets

MDT has been the topic of several analyst reports. Leerink Partnrs upgraded Medtronic to a "strong-buy" rating in a report on Monday, June 16th. Robert W. Baird decreased their price objective on Medtronic from $94.00 to $92.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Mizuho lifted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Evercore ISI lifted their price objective on Medtronic from $103.00 to $106.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Finally, Royal Bank Of Canada decreased their price objective on Medtronic from $105.00 to $101.00 and set an "outperform" rating on the stock in a report on Thursday, May 22nd. Eleven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $98.19.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.